Clinical trial
A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis
NCT00048932 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00048932 |
|---|---|
| Title | A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | Double-blind Abatacept, Double-blind Placebo, Open-label Abatacept |
| Enrollment | 1,795 |
| Start date | Dec 1, 2002 |
| Primary completion | Oct 1, 2009 |
| Completion | Oct 1, 2009 |
| First posted | Nov 13, 2002 |
| Last update posted | Nov 24, 2011 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: